Brief: Sensei Biotherapeutics Announces Collaboration With Washington University, St. Louis To Support Development Of SNS-101
21/11/2022 12:31
Nov 21 (Reuters) - Sensei Biotherapeutics Inc SNSE.O :
* SENSEI BIOTHERAPEUTICS ANNOUNCES COLLABORATION WITH
WASHINGTON
UNIVERSITY, ST. LOUIS TO SUPPORT DEVELOPMENT OF SNS-101, A
CONDITIONALLY ACTIVE VISTA-BLOCKING ANTIBODY
Source text for Eikon: ID:nGNX8r3Jld
Further company coverage: SNSE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Faeth Therapeutics,
See all newsBrief: Sensei Biotherapeutics Announces Name Change To Faeth Therapeutics
Brief: Sensei Biotherapeutics Doses First Patient In Phase 1B/2 Trial Of Piktor In Hr+/Her2- Advanced Breast Cancer
Brief: Sensei Biotherapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)